TI
MLYS icon

Trexquant Investment’s Mineralys Therapeutics MLYS Stock Holding History

Trexquant Investment’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.58M Buy
169,715
+112,515
+197% +$3.09M 0.03% 791
2026
Q1 		$1.55M Sell
57,200
-55,588
-49% -$1.63M 0.01% 1087
2025
Q4 		$4.09M Buy
112,788
+68,815
+156% +$2.76M 0.04% 681
2025
Q3 		$1.67M Sell
43,973
-138,692
-76% -$3M 0.02% 976
2025
Q2 		$2.47M Buy
182,665
+56,130
+44% +$813K 0.03% 816
2025
Q1 		$2.01M Buy
+126,535
New +$1.46M 0.02% 871

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Trexquant Investment's MLYS Position: Q2 2026 in Review

Trexquant Investment increased its Mineralys Therapeutics (MLYS) stake by 197% in Q2 2026, buying an estimated $3.09M and bringing the position to 169,715 shares worth $4.58M. The position accounts for 0.03% of the portfolio, ranked #791.

Trexquant Investment first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Trexquant Investment held 169,715 shares of Mineralys Therapeutics worth $4.58M as of Q2 2026.
  • Trexquant Investment bought 112,515 Mineralys Therapeutics shares in Q2 2026, an estimated $3.09M.
  • Mineralys Therapeutics made up 0.03% of Trexquant Investment's portfolio in Q2 2026, its #791 holding.
  • Trexquant Investment first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.